Voyager Therapeutics, Inc. President Robin Swartz filed a Form 4 on November 3, 2026, disclosing the acquisition of 68,250 restricted stock units and a stock option covering 318,500 shares of common stock, both granted on November 1, 2026 under the company's 2025 Stock Incentive Plan.

Key Highlights

  • RSU award: Robin Swartz acquired 68,250 restricted stock units at $0.00 cost on November 1, 2026, each representing the right to receive one share of common stock upon vesting.
  • Vesting schedule (RSUs): The RSU award vests over three years, with 1/3rd vesting on the one-year anniversary of the November 1, 2026 grant date and 1/3rd at the end of each successive one-year period thereafter.
  • Stock option granted: Swartz also acquired a stock option to purchase 318,500 shares of common stock at an exercise price of $1.72, expiring November 1, 2036.
  • Vesting schedule (option): The option vests over four years from an October 20, 2026 commencement date, with 1/48th vesting monthly beginning on the one-month anniversary of that date.
  • Post-transaction ownership: Following these transactions, Swartz directly beneficially owns 267,988 shares of common stock and 318,500 derivative securities.
  • Plan: Both awards were issued pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan.

Swartz RSU and Option Awards at Voyager Therapeutics: Transaction Details

According to the Form 4 filed with the SEC on November 3, 2026, Robin Swartz, President of Voyager Therapeutics, Inc. (NASDAQ:VYGR), received two equity awards on November 1, 2026. The first was an award of 68,250 restricted stock units granted at no cost under the company's 2025 Stock Incentive Plan. As described in the filing, each RSU represents the right to receive one share of common stock upon vesting, with the vesting commencement date set as the grant date of November 1, 2026.

The RSU award is scheduled to vest over three years: one-third of the underlying shares vest on the one-year anniversary of the grant date, with an additional one-third vesting at the end of each successive one-year period, subject, according to the filing, to Swartz's continued service. Following this acquisition, the filing reports Swartz directly holds 267,988 shares of common stock.

The second award disclosed is a stock option granting Swartz the right to purchase 318,500 shares of common stock at an exercise price of $1.72 per share, also acquired at $0.00 cost. The option expires November 1, 2036. The filing states the vesting commencement date for the option is October 20, 2026, with vesting occurring monthly over four years at a rate of 1/48th of the underlying shares per month, beginning on the one-month anniversary of the commencement date and continuing each successive month, subject to continued service. Both awards were granted under the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan.

What Was Disclosed

The filing reports two equity awards to Voyager Therapeutics President Robin Swartz: 68,250 RSUs and a stock option for 318,500 shares at $1.72, both granted November 1, 2026 under the 2025 Stock Incentive Plan, with post-transaction direct ownership of 267,988 shares of common stock.